发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
Lex. The benefits of next-generation peptides will be thinly spread
发布时间
29 天前
2026-09-09 04:00:07 UTC
源站更新
29 天前
2026-09-09 04:00:10 UTC
首次抓取
29 天前
2026-09-09 04:11:54 UTC
下一代多肽虽有望成为年销售额约 800 亿美元的大市场，但相关化合物难以获得专利保护，进入门槛低，利润将更接近消费品而非重磅药物。竞争将集中在品牌和价格，Hims 等具备一定先发优势，但消费品巨头可能入局。
Next-generation peptides could become an $80bn-a-year market, but because they cannot be patented, profits are likely to be thin and consumer-goods-like, with competition on branding and price. Hims has early advantages, but large consumer groups may enter once regulation clears.
用于追踪这条内容的来源与记录标识。
